Srikanth Seethala
Advanced Heart Failure and Transplant Cardiology · Boise, IDNPI 1982803292
Payments from drug & device makers
Across 313 payments — averaging $2196.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$434K
- E.r. Squibb & Sons, L.L.C.$125K
- Medtronic$111K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim International GmbH$5K
- Abbott$3K
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$74,25677%
- Travel & lodging$13,02514%
- Food & beverage$9,1589%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $434,166 |
| E.r. Squibb & Sons, L.L.C. | 98 | $125,205 |
| Medtronic(2 entities) | 30 | $110,595 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Boehringer Ingelheim International GmbH | 11 | $5,230 |
| Abbott | 63 | $2,794 |
| Abiomed | 12 | $1,002 |
| Actelion Pharmaceuticals US, Inc. | 51 | $335 |
| Novartis | 8 | $256 |
| AstraZeneca | 7 | $193 |
| United Therapeutics Corporation | 3 | $188 |
| Atricure, Inc. | 2 | $167 |
| Amgen | 1 | $147 |
| Bayer | 2 | $128 |
| Nuwellis, Inc. | 1 | $97 |
| One Lambda, Inc. | 1 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $56 |
| Boehringer Ingelheim | 2 | $48 |
| Endotronix, Inc. | 1 | $34 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$87,705
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$611
- CardioMEMS HF System$382
- Quadra Allure MP RF CRT Pacemkr$293
- HeartMate 3 Left Ventricular Dev$260
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$163
- HeartWare HVAD$155
- Repatha$147
- MitraClip System$134
- REMODULIN$122
- ENTRESTO$121
- WAINUA$113
- Impella$112
- Adempas$111
How this compares
Too few advanced heart failure and transplant cardiology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 67 | $532,476 |
| VyndamaxTafamidis | 16 | $375,629 |
| EntrestoSacubitril/Valsartan | 92 | $88,457 |
| JardianceEmpagliflozin | 67 | $60,259 |
| EliquisApixaban | 20 | $25,851 |
| FarxigaDapagliflozin Propanediol | 17 | $18,672 |
| Bumetanide | 31 | $1,475 |
| Ranolazine ErRanolazine | 21 | $1,415 |
| Metoprolol Succinate | 61 | $808 |
| Isosorbide Dinitrate | 12 | $502 |
| Carvedilol | 51 | $441 |
| Spironolactone | 77 | $401 |
| Torsemide | 18 | $292 |
| Potassium Chloride | 14 | $287 |
| Digoxin | 11 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $125,205 | $532,47667 claims |
| PfizerVyndamax, Eliquis | $19 | $401,48136 claims |
| NovartisEntresto | $256 | $88,45792 claims |
| Boehringer IngelheimJardiance | $48 | $60,25967 claims |
| AstraZenecaFarxiga | $193 | $18,67217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Boise
- Thomas KasprowiczBoise$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.